Eosinophilic inflammation plays a role in at least half of asthma and one-third of COPD flare-ups. For these people, targeting eosinophils when symptoms worsen is a promising strategy.

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

For the first time in half a century, scientists have hit on a new treatment for asthma attacks. Clinical trial results have ...

For the majority of people with asthma, symptoms are linked to high levels of eosinophilic inflammation. To identify this, ...

Asthma attacks and chronic obstructive ... The injection treat flare-ups called "eosinophilic exacerbation" and involve symptoms including wheezing, coughing and chest tightness due to ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

Scientists have found a new treatment for people with asthma and chronic obstructive pulmonary disease (COPD) that may be more effective than current options. Over the past 50 years, treatment options ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

Episodes of worsening respiratory symptoms in asthma or COPD, driven by high levels of eosinophils (white blood cells) that cause inflammation in the airways. Laboratory-engineered molecules that can ...

A new injection, benralizumab, outperforms traditional steroids in treating asthma and COPD attacks, reducing treatment ...